BIFIDO Co. Ltd (238200) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BIFIDO Co. Ltd (238200) has a cash flow conversion efficiency ratio of -0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-31.26 Million ≈ $-21.19K USD) by net assets (₩44.44 Billion ≈ $30.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 238200 market cap for the company's overall valuation and market capitalisation.
BIFIDO Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how BIFIDO Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BIFIDO Co. Ltd stock quote for real-time trading data and today's change.
BIFIDO Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIFIDO Co. Ltd ranked by their cash flow conversion efficiency. Review 238200 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yulho Co. Ltd
KQ:072770
|
-0.042x |
|
Prajay Engineers Syndicate Limited
NSE:PRAENG
|
0.053x |
|
CTRL Group Limited Ordinary Shares
NASDAQ:MCTR
|
-0.546x |
|
SPECO Ltd
KQ:013810
|
0.011x |
|
Batavia Prosperindo Trans Tbk PT
JK:BPTR
|
0.153x |
|
COCRYSTAL PHARMA NEW O.N.
F:8CC
|
-0.274x |
|
COSMOS HEALTH NEW DL-01
F:V67A
|
-0.249x |
|
Capital Point
TA:CPTP
|
-0.017x |
Annual Cash Flow Conversion Efficiency for BIFIDO Co. Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of BIFIDO Co. Ltd from 2016 to 2025. Also see BIFIDO Co. Ltd balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩45.93 Billion ≈ $31.13 Million |
₩3.95 Billion ≈ $2.68 Million |
0.086x | +660.57% |
| 2024-12-31 | ₩46.69 Billion ≈ $31.64 Million |
₩-716.29 Million ≈ $-485.42K |
-0.015x | -127.85% |
| 2023-12-31 | ₩51.70 Billion ≈ $35.04 Million |
₩2.85 Billion ≈ $1.93 Million |
0.055x | +54.19% |
| 2022-12-31 | ₩52.49 Billion ≈ $35.57 Million |
₩1.88 Billion ≈ $1.27 Million |
0.036x | -11.12% |
| 2021-12-31 | ₩50.64 Billion ≈ $34.32 Million |
₩2.04 Billion ≈ $1.38 Million |
0.040x | -3.97% |
| 2020-12-31 | ₩44.60 Billion ≈ $30.22 Million |
₩1.87 Billion ≈ $1.27 Million |
0.042x | -26.86% |
| 2019-12-31 | ₩46.29 Billion ≈ $31.37 Million |
₩2.65 Billion ≈ $1.80 Million |
0.057x | -46.13% |
| 2018-12-31 | ₩44.73 Billion ≈ $30.31 Million |
₩4.75 Billion ≈ $3.22 Million |
0.106x | -49.13% |
| 2017-12-31 | ₩18.50 Billion ≈ $12.53 Million |
₩3.86 Billion ≈ $2.62 Million |
0.209x | +0.49% |
| 2016-12-31 | ₩16.07 Billion ≈ $10.89 Million |
₩3.34 Billion ≈ $2.26 Million |
0.208x | -- |
About BIFIDO Co. Ltd
BIFIDO Co., Ltd. produces probiotics-based products in South Korea and internationally. It offers bifidobacterium strain products, such as BGN4 for immune modulating; BORI used to treat rotavirus infection in infants; and AD011 for general intestinal health problems. The company was founded in 1999 and is headquartered in Hongcheon-eup, South Korea.